# Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

> **NCT01107665** · PHASE2 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 60 (actual)

## Conditions studied

- Stage III Melanoma
- Stage IV Melanoma
- Unresectable Melanoma

## Interventions

- **DRUG:** Pazopanib and Paclitaxel

## Key facts

- **NCT ID:** NCT01107665
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107665, "Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01107665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*